Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of PDR001 in previously treated advanced nonfunctional neuroendocrine tumors
MOH_2017-03-14_000248Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in apudoma (NET), sponsored by Novartis. Primary endpoint: Objective response rate. Started Feb 2017; status: completed.
02
Drugs
spartalizumab
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on MOH_2017-03-14_000248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000248.